Richardpruen (talk | contribs) (→Cognitive / IQ / Memory: Add study showing that the cognitive benefits of vaping are the same as cigarettes; thus, vapes provide a vastly safer, acceptable alternative to cigarettes.) |
|||
| (3 intermediate revisions by the same user not shown) | |||
| Line 30: | Line 30: | ||
<br> | <br> | ||
='''ADD / ADHD / Attention'''= | ='''ADD / ADHD / Attention / Cognition'''= | ||
===2018 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018192/ Cognitive Effects of Nicotine: Recent Progress]=== | ===2018 [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6018192/ Cognitive Effects of Nicotine: Recent Progress]=== | ||
| Line 733: | Line 733: | ||
*Nicotine is a nonselective agonist of the α7Ach receptor and is able to suppress the production of proinflammatory cytokines by mimicking the binding of acetylcholine. It has been demonstrated that nicotine can selectively reduce the inflammatory response in a number of infection scenarios, including Legionella pneumophila (54) and Chlamydia pneumoniae (55) infection... | *Nicotine is a nonselective agonist of the α7Ach receptor and is able to suppress the production of proinflammatory cytokines by mimicking the binding of acetylcholine. It has been demonstrated that nicotine can selectively reduce the inflammatory response in a number of infection scenarios, including Legionella pneumophila (54) and Chlamydia pneumoniae (55) infection... | ||
*Citation: D'Elia, R. V., Harrison, K., Oyston, P. C., Lukaszewski, R. A., & Clark, G. C. (2013). Targeting the "cytokine storm" for therapeutic benefit. Clinical and vaccine immunology : CVI, 20(3), 319–327. https://doi.org/10.1128/CVI.00636-12 | *Citation: D'Elia, R. V., Harrison, K., Oyston, P. C., Lukaszewski, R. A., & Clark, G. C. (2013). Targeting the "cytokine storm" for therapeutic benefit. Clinical and vaccine immunology : CVI, 20(3), 319–327. https://doi.org/10.1128/CVI.00636-12 | ||
<br> | |||
='''ME/CFS Myalgic Encephalomyelitis/Chronic Fatigue Syndrome'''= | |||
*See Also: COVID (Long COVID) | |||
<br> | <br> | ||
| Line 1,300: | Line 1,304: | ||
='''Suggested additions to this page'''= | ='''Suggested additions to this page'''= | ||
===2021: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183099/ Transdermal nicotine in non-smokers: A systematic review to design COVID-19 clinical trials]=== | |||
===2008: [https://pubmed.ncbi.nlm.nih.gov/19011436/ Efficacy of a nicotine (4 mg)-containing lozenge on the cognitive impairment of nicotine withdrawal]=== | |||
===2024: [https://harmreductionjournal.biomedcentral.com/articles/10.1186/s12954-024-00993-0 An exploratory, randomised, crossover study to investigate the effect of nicotine on cognitive function in healthy adult smokers who use an electronic cigarette after a period of smoking abstinence]=== | |||
===2023: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10602090/ Butyrate protects and synergizes with nicotine against iron- and manganese-induced toxicities in cell culture: Implications for neurodegenerative diseases]=== | ===2023: [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10602090/ Butyrate protects and synergizes with nicotine against iron- and manganese-induced toxicities in cell culture: Implications for neurodegenerative diseases]=== | ||
edits